SCHEMBL378900

SCHEMBL378900

CCN(CCO)CCCCNC(=O)Nc1snc(OCc2c(F)cc(Cl)cc2F)c1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.47
EGFR P00533 4/20 0.47
FGFR1 P11362 3/20 0.47
ABL1 P00519 2/20 0.47
RET P07949 2/20 0.47
PDGFRB P09619 2/20 0.47
SRC P12931 2/20 0.47
FGFR2 P21802 2/20 0.47
FGFR4 P22455 2/20 0.47
FGFR3 P22607 2/20 0.47
FLT1 P17948 2/20 0.47
PLK4 O00444 1/20 0.47
AURKA O14965 1/20 0.47
EPHB6 O15197 1/20 0.47
RIPK2 O43353 1/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
INSR P06213 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5344917 0.93 KDR (0.48) KDREGFRFGFR1ABL1RET
SCHEMBL378585 0.92 KDR (0.56) KDREGFRFGFR1ABL1RET
SCHEMBL3083938 0.91 KDR (0.56) KDREGFRFGFR1ABL1RET
SCHEMBL378590 0.90 KDR (0.43) KDREGFRFGFR1ABL1RET
SCHEMBL378013 0.89 KDR (0.44) KDREGFRFGFR1ABL1RET
SCHEMBL378282 0.89 KDR (0.49) KDREGFRFGFR1ABL1RET
SCHEMBL378723 0.88 EGFR (0.41) KDREGFRFGFR1ABL1RET
SCHEMBL3096969 0.87 KDR (0.59) KDREGFRFGFR1ABL1RET
SCHEMBL378412 0.86 KDR (0.44) KDREGFRFGFR1ABL1RET
SCHEMBL378011 0.86 KDR (0.39) KDREGFRFGFR1ABL1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371298-B2 Processes for the preparation of isothiazole derivatives PFIZER INC. (US) 2016-06-21 US claimed
US-20150065726-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER INC. 2015-03-05 US claimed
EP-1784183-B1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER (US) 2012-01-25 EP claimed
US-20090023924-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER INC. 2009-01-22 US claimed
EP-1784183-A2 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES Pfizer Products Incorporated (US) 2007-05-16 EP claimed
WO-2006026034-A2 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER PRODUCTS INC. (US) 2006-03-09 WO claimed
US-9371298-B2 Processes for the preparation of isothiazole derivatives PFIZER INC. (US) 2016-06-21 US disclosed
US-20150065726-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER INC. 2015-03-05 US disclosed
US-8884025-B2 Processes for the preparation of isothiazole derivatives PFIZER INC. 2014-11-11 US disclosed
EP-1784183-B1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER (US) 2012-01-25 EP disclosed
US-20090023924-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER INC. 2009-01-22 US disclosed
EP-1784183-A2 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES Pfizer Products Incorporated (US) 2007-05-16 EP disclosed
WO-2006026034-A2 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES PFIZER PRODUCTS INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023924-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES CYP3A4, CYP3A43, CYP2F1 KDR 2551/4885EGFR 2494/4885FGFR1 415/4885
US-20150065726-A1 PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES CYP3A4, CYP3A43, CYP2F1 KDR 2246/4885EGFR 2367/4885FGFR1 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.